- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
- Senate passes Drug Quality and Security Act
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
- Reports: ESI may start 'price war' over new hepatitis C drugs
MONMOUTH JUNCTION, N.J. — Tris Pharma has hired a former buyer from AmerisourceBergen to head its generic drug business, the company said.
Tris announced the appointment of Janet Penner as president of the new generic pharmaceuticals business, which will have its own sales, marketing and distribution and will be responsible for bringing drugs to market. So far, the Food and Drug Administration has approved 13 of Tris' generics, including several first-to-market products.
"Tris' generics initiative is a natural evolution of the overall strategic vision at Tris, bringing technologically challenging, high-quality products to the marketplace," Tris president and CEO Ketan Mehta said.
Janet has worked in generic drugs for nearly 15 years, including her generics purchasing role at AmerisourceBergen and as head of sales and marketing at CorePharma.
"Tris' unique technology for liquid sustained-release products, along with the continued expansion of its strategic pipeline of both liquid and solid oral dosage [abbreviated new drug application] development projects, has me truly excited to spearhead the generic pharmaceuticals business at Tris," Penner said.